Week in Review: Aslan In-Licenses Novel Asthma mAb from CSL

Aslan Pharma of Singapore acquired global rights to develop a novel monoclonal antibody to treat asthma from Australia’s CSL Limited; NeoStem out-licensed China rights for its liver cancer immunotherapy to Cellular Biomedicine of China; CSPC Pharma partnered with Dexcel Pharma of Israel to co-develop Dexcel’s oncology drug; Lannett Company, a US generic drugmaker, signed bilateral distribution and CMO with HEC Pharm Group of Shenzhen; ChinaBio® reported record attendance of 848 delegates at its 2014 Partnering Forum, which concluded last week in Suzhou; Hengrui Medicine received CFDA permission to begin China clinical trials of a cancer biosimilar drug; DelMar Pharma advanced its lead brain cancer treatment, which is sourced from Wuzhou Pharma, into a new dosage level in a Phase I/II trial; and WuXi PharmaTech completed construction of its new Suzhou biologics biosafety testing facility. More details.... Stock Symbols: (ASX: CSL) (NSDQ: NBS) (OTCQB: CBMG) (HK: 1093) (NYSE: LCI) (SHA: 600276) (NYSE: WX) Share this with colleagues: // //